Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.75
Bid: 13.50
Ask: 14.00
Change: -0.25 (-1.79%)
Spread: 0.50 (3.704%)
Open: 14.00
High: 14.00
Low: 13.75
Prev. Close: 14.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Venture Company

17 May 2006 07:00

Angle PLC17 May 2006 For Immediate Release 17 May 2006 ANGLE plc ('ANGLE' or 'the Company') New Venture Company: Kaloptics, Inc. ANGLE plc ('ANGLE'), the venture management and consulting company specialising in the commercialisation of technology, is pleased to announce that it has signed an agreement with New York University (NYU) to commercialise innovative technology developed at the Media Research Lab in the Computer Science Department of NYU's Courant Institute of Mathematical Sciences. The agreement was effective on 30 April but for reasons of commercial confidentiality was embargoed until now. Researchers Ken Perlin, PhD and Jeff Han have developed a patent-pendingkaleidoscope and software system that enables the rapid capture and recreationof photo-realistic surface images. The technology has a wide range of commercialapplications in multi-billion dollar industries, including special effects,animation, computer gaming and medical devices. As part of its normal model for venture creation, ANGLE has formed and willincubate Kaloptics, Inc. to lead the technology commercialisation, market and IPassessment, and business strategy. ANGLE will contribute the initial managementof Kaloptics and lead a seed financing round for the company. Ken Perlin is a professor in the Department of Computer Science at NYU and wasfounding director of its Media Research Lab. His research interests includegraphics, animation, user interfaces and multimedia. He also received an AcademyAward for Technical Achievement from the Academy of Motion Picture Arts andSciences. Jeff Han, a computer science researcher at NYU, has been working in the fieldsof real-time computer graphics, computer vision, human-computer interfaces andmachine learning for over ten years. ANGLE's Chief Executive, Andrew Newland, said: "We are delighted to be working with New York University and its Media ResearchLab. These are world-class researchers who have produced numerous contributionsto their fields. We believe that the Kaleidoscope system can address a majorissue in multiple markets - the cost effective acquisition of data that can beused for the creation of realistic surface images." For further information ANGLE plc +44 1483 295830Andrew Newland, Chief ExecutiveRob Kornblum, Managing Director US Ventures Buchanan Communications +44 20 7466 5000Richard Darby, Suzanne Brocks, James Strong, Amy Rajendran Note to editors: About ANGLE Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE operates from offices inthe UK, the US and the Middle East. ANGLE is listed on AIM (AGL.L); further information can be found atwww.angleplc.com About NYU New York University, located in the heart of Greenwich Village, was establishedin 1831 and is one of America's leading research universities and a member ofthe selective Association of American Universities. It is one of the largestprivate universities, it is a leader in attracting international students andscholars in the U.S, and it sends more students to study abroad than any otherU.S. college or university. Through its 14 schools and colleges, NYU conductsresearch and provides education in the arts and sciences, law, medicine,business, dentistry, education, nursing, the cinematic and performing arts,music, public administration, social work, and continuing and professionalstudies, among other areas. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
23rd Dec 20199:55 amRNSIssue of Equity
7th Nov 20197:00 amRNSCancer centre shows Parsortix use in melanoma
30th Oct 20192:44 pmRNSResult of AGM
30th Oct 20197:00 amRNSQ-submission to FDA containing headline data
8th Oct 20197:00 amRNSNotice of AGM
4th Oct 20195:54 pmRNSHolding(s) in Company
4th Oct 20197:00 amRNSEuropean patent granted for megakaryocyte analysis
13th Sep 20197:00 amRNSUse of Parsortix in head and neck cancer
10th Sep 20197:00 amRNSResearch with Parsortix in prostate cancer
4th Sep 20197:00 amRNSParsortix for Neuroendocrine Analysis in SCLC
29th Aug 20197:00 amRNSInitiation of Ovarian Cancer Study
31st Jul 20197:00 amRNSPrelim Results for the year ended 30 April 2019
22nd Jul 20197:00 amRNSUse of Parsortix for single cell analysis of CTCs
16th Jul 20199:19 amRNSHolding(s) in Company
12th Jul 201910:22 amRNSResult of General Meeting anf Total Voting Rights
28th Jun 20191:37 pmRNSNotice of Preliminary Results and Webcast
28th Jun 20191:08 pmRNSHolding(s) in Company
25th Jun 20195:19 pmRNSResult of Placing
25th Jun 20198:02 amRNSAccelerated bookbuild to raise £18.0m
21st Jun 20197:00 amRNSParsortix used to investigate immunotherapy target
5th Jun 20197:00 amRNSCompletion of Ovarian Cancer Pre-Study
31st May 20197:00 amRNSPositive Results from FDA Clinical Study
26th Apr 20197:00 amRNSIMMUNE SUPPRESSOR CELLS PROMOTE METASTASIS
18th Apr 20197:00 amRNSParsortix used in new cancer assessment technique
12th Apr 20197:00 amRNSLUNG CANCER STUDY USES ANGLE'S PARSORTIX SYSTEM
4th Apr 20197:00 amRNSAACR 2019
11th Mar 20197:00 amRNSHolding(s) in Company
7th Mar 20197:00 amRNSENROLMENT COMPLETE FOR FDA CLINICAL STUDY
28th Feb 20197:00 amRNSFIRST SUBJECTS ENROLLED IN OVARIAN CANCER STUDY
25th Feb 20197:00 amRNSCUSTOMER DEMONSTRATES NEW USE FOR PARSORTIX
11th Feb 20197:00 amRNSResearch into role of immune cells in cancer
31st Jan 20197:00 amRNSInterim Results
29th Jan 20197:00 amRNSNEW APPLICATION FOR PARSORTIX IN CANCER ANALYSIS
11th Jan 20192:05 pmRNSSecond Price Monitoring Extn
11th Jan 20192:00 pmRNSPrice Monitoring Extension
11th Jan 201911:05 amRNSSecond Price Monitoring Extn
11th Jan 201911:00 amRNSPrice Monitoring Extension
11th Jan 20199:05 amRNSSecond Price Monitoring Extn
11th Jan 20199:00 amRNSPrice Monitoring Extension
10th Jan 20194:41 pmRNSSecond Price Monitoring Extn
10th Jan 20194:36 pmRNSPrice Monitoring Extension
10th Jan 20194:01 pmRNSBREAKTHROUGH CANCER RESEARCH USING PARSORTIX
9th Jan 20197:00 amRNSNotice of Results
21st Dec 20187:00 amRNSIssue of LTIP Options and Share Options
28th Nov 20187:00 amRNSLEADING US HEMATOPATHOLOGIST APPOINTED AS ADVISOR
13th Nov 20185:10 pmRNSHolding(s) in Company
5th Nov 20187:00 amRNSAcquisition of outstanding shares
2nd Nov 20182:00 pmRNSPrice Monitoring Extension
1st Nov 20187:00 amRNSAppointment of Dr Jan Groen as NED
30th Oct 20184:21 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.